Cirdan Buys ULTRA Lab Information System from GE
News Oct 18, 2013
Northern Irish company Cirdan has acquired the intellectual property and assets of GE Healthcare's Centricity laboratory division, including the Centricity laboratory information system (LIS) known as ULTRA that is widely used in Australia.
As part of the acquisition, Cirdan will continue to support users of the current version of ULTRA, which include the governments of Western Australia and South Australia as well as Healthscope and Primary Health Care.
ULTRA was first launched in Australia in the 1980s by original developer Triple G Systems, which was acquired by GE in 2003.
Cirdan CEO Hugh Cormican said the company planned to further develop the Centricity product range to keep pace with rapid advances in molecular and genetic pathology.
Cirdan will launch version 5 of ULTRA in January 2015. Mr Cormican said this version will be partially developed in Australia, where the company is in the process of setting up an office.
“This will combine the power and performance of the GE LIS products with the pathology imaging modalities under development by Cirdan Imaging,” Mr Cormican said.
Cirdan has set up a subsidiary, Cirdan Ultra, as part of the acquisition, which also involved Bel fast-based digital technology solutions provider Kainos Software.
The Genes That Make Quorn a Fungal Food FavoriteNews
The meat substitute Quorn is derived from a fungus called Fusarium venenatum. A very similar fungus, F. graminearum, is one of the world's most damaging crop diseases. A new genome study shows why one fungus makes food, and the other destroys it.READ MORE
Neural Computer Hears Like HumansNews
Modelling the human senses is an incredibly complex task. Our brains arrange cells into complex hierarchies that process information from our surroundings. Now, a group at MIT have created a model of the human auditory cortex that can hear sounds and music in the same way that humans do.READ MORE
Stable Beta-Amyloid Dimers Identified in Alzheimer’s BrainsNews
A recent study exploited state-of-the-art mass spectrometry to provide the first direct evidence of beta-amyloid dimers in patients with Alzheimer’s disease and points to the potential of these molecules as biomarkers. Beta-amyloid dimers may be the smallest pathological species that trigger Alzheimer’s disease.
Comments | 0 ADD COMMENT
International Conference on Analytical and Bio Analytical Techniques
Oct 31 - Nov 01, 2018